We thank Avidan et al.  for their interest in our study and for the opportunity to respond to their concerns, many of which had already been addressed in our article.1To begin with, we fully agree that recent studies have highlighted the need for control groups to separate the effects of surgery from aging or underlying disease. Unfortunately, at the time of study inception, a control group was not included, largely as a result of the budgetary limits imposed by the National Institutes of Health. The financial challenges associated with pursuing prospective randomized controlled trials are formidable and frequently mandate other designs, as is evidenced by Dr. Avidan's own retrospective  work on cognitive dysfunction.2There is also controversy in longitudinal studies as to the appropriate control group and how large it would need to be to minimize crossover. In addition, our primary hypothesis examined the effect of APOE4 genotype upon cognition; therefore, the non-APOE4 subjects were, in effect, the control group. Although the overall rate of cognitive dysfunction may be higher without a “true control group,” our finding of no significant effect of APOE4 genotype is still valid.

Second, Avidan et al.  object to an arbitrary statistical threshold for the diagnosis of postoperative cognitive dysfunction (POCD). Defining POCD as deficit or no-deficit requires specifying a cutoff for amount of decline. In the absence of a criterion standard, any cutoff is arbitrary. We believe a decline of more than 1 SD represents a clinical and noticeable loss in cognitive function. First, in an assessment in which most patients improve over time, any decline is bad. Further, in other samples, we have seen a significant association between our defined POCD and cognitive difficulty reported by patients themselves in a 39-item assessment of perceived problems in memory, concentration, attention, and psychomotor coordination. The questionnaire includes items such as “I forget errands I planned to do” and “I fail to recognize people I know.” A higher score is worse. Patients we classified as having POCD had a mean increase [mean (SD)] of +1.64 (22.1) in difficulties at 6 weeks after surgery, whereas no-POCD patients had a mean decrease of −2.54 (19.4), P = 0.02. A trend toward increased mortality at 1 yr in patients with POCD (3.16 vs . 1.25%, P = 0.23) was also reported in our article. Thus, our choice of a 1 SD decline does have some clinical relevance. Nevertheless, because any threshold is arbitrary in the absence of a criterion standard, we have also examined a continuous change score, which is calculated by subtracting the baseline from the follow-up cognitive index (mean of the four domain scores). As with the dichotomous outcome, there is no association between APOE4 and cognitive change, once again validating our finding of no significant effect of APOE4 genotype.

Third, the issue of baseline “mild dementia” was raised. As Avidan and colleagues2have demonstrated, baseline mild cognitive impairment or dementia may be confounders when assessing long-term POCD. However, this cognitive impairment can be in single or multiple cognitive domains and can have a variety of clinical manifestations.3,4The International Working Group on Mild Cognitive Impairment published their first efforts toward a consensus in this arena in 2004,3but only near the completion of our study. Gauthier et al.  4have more recently highlighted the ongoing uncertainty and debate in this field, noting in particular that “the prognosis in terms of progression to dementia is more heterogeneous in population studies than in the setting of specialized clinics (such as an Alzheimer's Disease Research Center ) and is driven by the nosological and exclusionary criteria being used in either setting.” At the very least, further studies defining and validating the effects of baseline dementia are still needed. In our study focused on shorter-term cognitive dysfunction, we compared postoperative cognition with preoperative baseline values to make each patient his/her own “control” while acknowledging the inherent limitations to this approach.

Fourth, the etiology of POCD remains incompletely ascertained at this time, as Dr. Avidan points out. We do think, however, that it is inappropriate to conclude from our study that anesthetic factors have no effect on POCD because our study was not designed to examine that hypothesis. Thus, we made no conclusions regarding the etiology of POCD. We simply found no association between APOE4 genotype, as well as a panel of serum biomarkers, and postoperative cognitive decline, assessed either as a dichotomous or a continuous measure.

Fifth, Avidan et al.  requested greater detail on the factor loadings used in our cognitive analyses; these are provided in table 1.We did not publish this table because we believed it would not be meaningful or interpretable to most readers. Trails-Making B scores were reversed to scale all scores, where higher is better, and log-transformed to obtain a normal distribution. After Varimax orthogonal rotation, all loadings (factor pattern matrix) are therefore positive.

Table 1.  Factor Loadings and Weights for the Neurocognitive Test Battery

Table 1.  Factor Loadings and Weights for the Neurocognitive Test Battery
Table 1.  Factor Loadings and Weights for the Neurocognitive Test Battery

Sixth, Avidan et al.  objected to our definition of POCD and the high POCD rate that we reported. We note that 74% of our patients underwent orthopedic surgery where embolic phenomenon are reported to be more common and may account for at least a portion of the higher incidence seen in our study. Although Avidan et al.  focus on the categorical outcome, we again emphasize that we have also presented a continuous measure of change, which expresses both the amount and the direction of change (decline and improvement) and reflects the continuous nature of cognitive functioning. We include a dichotomous definition of POCD to satisfy the need for descriptive categorization. Our categorical cognitive outcome is also intentionally inclusive. Like many medical adverse events, it is focused on identifying injury and is not ameliorated or offset by improvement in other areas. A broken arm should not be ignored or classified differently because the other arm is whole or gains compensatory strength during recovery. Thus, it is a strength of our study that we present two different means of characterizing postsurgical cognitive change; in the end, neither measure supports an effect of APOE4.

Certainly for the categorized outcome, as with any composite outcome, the number of domains influences the likelihood of observing an event. Our choice of four domains is driven directly by the tests in our battery, which are grouped very coherently in domains. The battery was chosen by clinical consideration as representative of important distinct cognitive functions. At 6 weeks, 90% (171 of 190) of patients classified as having POCD had a deficit in one factor only; none had deficits in more than two factors. Improvement of more than 1 SD on at least one factor was seen in 59% of all patients (206 of 350); 25 improved more than 1 SD on two factors. At 1 yr, 57% (166 of 291) of patients showed improvement of more than 1 SD on at least one factor. Once again, in keeping with the medical model of injury, a decline in any important domain of cognitive functioning is arguably noteworthy and should not be ignored because of improvement or compensation in other domains.

Seventh, Avidan et al.  stated that the reported incidence rate of POCD in our study was inconsistent with the change scores on the continuous cognitive index. We appreciate the thoughtful attention to the difference between the continuous change score and the dichotomous categorization but note that they are, to some degree, “comparing apples to oranges.” As discussed above, the continuous score quantifies overall response, without the necessity of an arbitrary cutoff for decline. It allows improvement in some individuals to offset others' decline in characterizing the group response. The dichotomous categorization identifies cognitive decline more specifically both in individuals and in domains. We appreciate the “glass almost full” perspective of the critique in respect to cognitive recovery but also are concerned about patients whose function may no longer be complete.

Finally, Avidan et al.  were concerned about the time course of POCD. Of those with POCD at 6 weeks, 51% (74 of 145) also had it at 1 yr; 43% of those without POCD at 6 weeks (56 of 129) had it at 1 yr. Just two postoperative observations provide very little information for reliably estimating the time course of POCD, and this was not the intention of our study. All of these subjects are being obeserved to 5 yr, and these data will be published when available.

Although we applaud the contributions of Avidan and colleagues to our understanding of the role of dementia in POCD, we encourage them to join us and the many other established research groups assessing POCD in conducting the rigorous prospective surgical trials necessary to provide conclusive answers. We also forcefully reject their assertion that our findings are meaningless. By focusing on our dichotomous categorization and virtually ignoring the fact that a continuous measure was also assessed, they are employing a strategy of misdirection that is unwarranted. In contrast to their mere “hope for truth,” we have prospectively enrolled 394 patients to demonstrate that the APOE4 genotype is not associated with cognitive decline after noncardiac surgery.

*Duke University Medical Center, Durham, North Carolina. david.mcdonagh@duke.edu

McDonagh DL, Mathew JP, White WD, Phillips-Bute B, Laskowitz DT, Podgoreanu MV, Newman MF, Neurologic Outcome Research Group: Cognitive function after major noncardiac surgery, apolipoprotein E4 genotype, and biomarkers of brain injury. Anesthesiology 2010; 112:852–9
Neurologic Outcome Research Group
Avidan MS, Searleman AC, Storandt M, Barnett K, Vannucci A, Saager L, Xiong C, Grant EA, Kaiser D, Morris JC, Evers AS: Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology 2009; 111:964–70
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment–beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256:240–6
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B, International Psychogeriatric Association Expert Conference on mild cognitive impairment: Mild cognitive impairment. Lancet  2006;367:1262–70
International Psychogeriatric Association Expert Conference on mild cognitive impairment